NEXTCURE INC (NXTC)
US65343E1082 - Common Stock
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences...
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations...
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND)...
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3...
NXTC Stock Earnings: NextCure Misses EPS for Q2 2024
NXTC stock results show that NextCure missed analyst estimates for earnings per share the second quarter of 2024.
NXTC Stock Earnings: NextCure Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NextCure (NASDAQ:NXTC) just reported results for the second quarter of 2024.Nex...
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment...
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7...
NXTC Stock Earnings: NextCure Misses EPS for Q1 2024
NXTC stock results show that NextCure missed analyst estimates for earnings per share the first quarter of 2024.
NXTC Stock Earnings: NextCure Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NextCure (NASDAQ:NXTC) just reported results for the first quarter of 2024.Next...
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR...
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure, Inc. (Nasdaq: NXTC) will present phase 1b data of NC410 in combination with pembrolizumab at ASCO 2024. ...
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74...
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering...
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering...
Wall Street’s Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The market is surging higher after dovish Fed comments. Here are seven of Wall Street’s favorite penny stocks that can help make you rich
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
NXTC stock results show that NextCure beat analyst estimates for earnings per share the fourth quarter of 2023.
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NextCure (NASDAQ:NXTC) just reported results for the fourth quarter of 2023.Nex...